

REMARKS

In an Office Action dated April 11, 2007, claims 1-3, 6, 7, 9 and 10, all of the claims then under consideration, were rejected. In view of the above amendments and the following remarks, Applicants respectfully request reconsideration of this Application, and allowance of the presently pending claims.

Claims 1-3, 6, 7, 9 and 10 were rejected under 35 U.S.C. §103(a) as being unpatentable over Carter in view of WO 92/00743. Claims 1-3, 6, 7, 9 and 10, under 35 U.S.C. §103(a) as being unpatentable over Carter in view of U.S. Patent No. 6,303,596. In the last paragraph on page 6 of the Office Action, under "Allowable Subject Matter", it is indicated that favorable consideration would be given to claims limited to the inhibition of colo-rectal tumor growth by administering a combination of 5-FU and taurolidine. By amendment above, all the claims have been amended as recommended in the Office Action. In view thereof, it is believed that all of the presently pending claims, as amended, are allowable.

In response to the obviousness-type double patenting rejection, submitted herewith is a terminal disclaimer in respect of commonly-owned U.S. Patent No. 6,479,481.

Applicants submit that the present Application is now in condition for allowance.

Reconsideration and favorable action are earnestly requested.

Respectfully submitted,

By: /s/ George R. Repper/
George R. Repper
Registration No. 31,414
Attorney for Applicants
Rothwell, Figg, Ernst & Manbeck, P.C.
1425 K Street, N.W., Suite 800
Washington, DC 20005
Telephone: (202) 783-6040
Fax: (202) 783- 6031

1421412